Compare Amgen, Inc. (AMGN) vs Opendoor Technologies Inc (OPEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Opendoor Technologies Inc — how do they compare? Amgen, Inc. trades at $360.83 (market cap $196.12B), while Opendoor Technologies Inc trades at $4.5 (market cap $4.60B). The key difference: Amgen, Inc. is far larger — about 42.6× Opendoor Technologies Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Opendoor Technologies Inc pays none. Which is the better fit depends on your goals.
| AMGN | OPEN | |
|---|---|---|
Market Cap | $196.12B | $4.60B |
Sector | Health | Real Estate |
52-Week High | $388.16 | $10.52 |
52-Week Low | $271.18 | $0.78 |
Enterprise Value | $241.41B | $4.94B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Opendoor Technologies (OPEN) trades at $4.485, down 5.86% today, with a neutral technical signal and bearish moving averages. The company reported Q1 2026 revenue of $4.37 billion but a net loss of $1.30 billion, reflecting a -35.25% net margin. Recent news highlights CEO commentary on housing market challenges and a shift to AI-driven operations after closing India units. Cash flow improved to $538 million net in 2025, though debt remains elevated at 54.54% of assets.
Outlook is cautious: analyst consensus is 65% hold with high execution risks in a tough housing market. Opportunities include AI efficiency gains and margin improvements, but persistent losses and macro headwinds like interest rates pose significant downside. The stock’s low P/S of 1 may attract value seekers if turnaround progresses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Opendoor Technologies Inc
Opendoor Technologies Inc is a digital platform for residential real estate. This platform enables customers to buy and sell houses online. It generates revenue through home sales, along with other revenue from real estate services.
Read more on OPEN →
